Update on the use of deferasirox in the management of iron overload

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 857-868

  Taher, Ali ^a   Cappellini, Maria Domenica ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiac iron; Deferasirox; Exjade; Iron chelation; Iron overload; Oral

Indexed keywords

CREATININE; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; RITONAVIR; STEROID;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APLASTIC ANEMIA; AREA UNDER THE CURVE; BETA THALASSEMIA; BLACKFAN DIAMOND ANEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FERRITIN BLOOD LEVEL; HEALTH ECONOMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INJECTION SITE PAIN; IRON BLOOD LEVEL; IRON OVERLOAD; LIVER FAILURE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PROGNOSIS; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 77749317208     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s5497     Document Type: Review

References (85)

1. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115(2):239-252.
2. Pootrakul P, Kitcharoen K, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood. 1988;71(4):1124-1129.
3. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36.
4. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574-578.
5. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-761.
6. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of non compliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919-1929.
7. Ferriprox. Summary of Product Characteristics. Apotex; 1999.
8. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118(1):330-336.
9. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583-1587.
10. Duffy-Warren F, Chesi A, Rigourd S, Frederick A. Exjade® (deferasirox) Basic Prescribing Information. URL http://www exjade com/index jsp 2008.
11. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003;10(12):1065-1076.
12. Steinhauser S, Heinz U, Bartholoma M, Weyhermüller T, Nick H, Hegetschweiler K. Complex formation of ICL670 and related ligands with FeIII and FeII. Eur J Inorg Chem. 2004;21:4177-4192.
13. Glickstein H, El BR, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108(9):3195-3203.
14. Wood JC, Otto-Duessel M, Gonzales I, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res. 2006;148(5):272-280.
15. Nick H, Wong A, Acklin P, et al. ICL670A: preclinical profile. Adv Exp Med Biol. 2002;509:185-203.
16. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873-880.
17. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol. 2003;43(6):565-572.
18. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003 10;361(9369):1597-1602.
19. Galanello R, Piga A, Cappellini MD, et al. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol. 2008;48(4):428-435.
20. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107(9):3455-3462.
21. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica. 2006;91(10):1343-1351.
22. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
23. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508.
24. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009; 82(6):458-465.
25. Taher A, El-Beshlawy A, Elalfy M, et al. Deferasirox significantly reduces iron burden in heavily iron-overloaded patients with beta-thalassaemia: 2.7 year results from the ESCALATOR study. Haematologica. 2009; 94(Suppl 2):abstr 209.
26. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: Prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2009. In press.
27. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood. 2008; 111(2):583-587.
28. Cappellini MD, Galanello R, Piga A, et al. Efficacy and safety of deferasirox (Exjade®) with up to 4.5 years of treatment in patients with thalassemia major: a pooled analysis. Blood. 2008;112(11):abstr 5411.
29. Piga A, Forni GL, Kattamis A, et al. Deferasirox (Exjade®) in pediatric patients with β-thalassemia: update of 4.7-year efficacy and safety from extension studies. Blood. 2008;112(11):abstr 3883.
30. Cappellini MD, Elalfy MS, Kattamis A, et al. Efficacy and safety of once-daily, oral iron chelator deferasirox (Exjade®) in a large group of regularly transfused patients with β-thalassemia major. Blood. 2008;112(11):abstr 3878.
31. Gattermann N, Schmid M, Della Porta M, et al. Efficacy and safety of deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial. Blood. 2008;112(11):abstr 633.
32. Lee JW, Yoon SS, Shen ZX, et al. Iron chelation in regularly transfused patients with aplastic anemia: efficacy and safety results from the large deferasirox EPIC trial. Blood. 2008;112(11):abstr 439.
33. Porter JB, Lin KH, Habr D, Domokos G, Hmissi A, Thein SL. Deferasirox efficacy and safety for the treatment of transfusion-dependent iron overload in patients with a range of rare anemias. Blood. 2008;112(11):abstr 1419.
34. Porter JB, Forni GL, Beris P, et al. Efficacy and safety of 1 year's treatment with deferasirox (Exjade®): assessment of regularly transfused patients with Diamond-Blackfan anemia enrolled in the EPIC study. Blood. 2008;112(11):abstr 1048.
35. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009. [Epub ahead of print].
36. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
37. Pathare A, Taher A, Daar S. Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol. 2009. [Epub ahead of print].
38. Roghi A, Cassinerio E, Proto P, et al. The effect of deferasirox on myocardial iron overload and cardiac function: a prospective independent monocentric study using cardiovascular magnetic resonance T2* (MRI T2*). Haematologica. 2009;94(Suppl 2):abstr 762.
39. Wood J, Thompson A, Paley C, et al. Deferasirox reduces cardiac iron burden in chronically transfused β-thalassemia patients with mild-to-moderate cardiac siderosis as demonstrated by MRI T2*. Haematologica. 2009;94(Suppl 2):abstr 763.
40. Eleftheriou P, Tanner M, Pennell D, Porter JB. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis. Haematologica. 2006;91(Suppl 1):abstr 999.
41. Pennell D, Porter JB, Cappellini MD, et al. Efficacy and safety of deferasirox (Exjade®) in reducing cardiac iron in patients with β-thalassemia major: results from the cardiac substudy of the EPIC trial. Blood. 2008;112(11):abstr 3873.
42. Pennell D, Sutcharitchan P, El-Beshlawy A, et al. Efficacy and safety of deferasirox (Exjade®) in preventing cardiac iron overload in β-thalassemia patients with normal baseline cardiac iron: results from the cardiac substudy of the EPIC trial. Blood. 2008;112(11): abstr 3874.
43. Ladis V, Berdoussi H, Kattamis A. Treatment with deferasirox for nontransfusional iron overload in patients with thalassemia intermedia. Haematologica. 2009;94(Suppl 2):abstr 1279.
44. Voskaridou E, Konstantinidou M, Douskou M, et al. Treatment with deferasirox effectively decreases iron burden in patients with thalassemia intermedia. Haematologica. 2009;94(Suppl 2):abstr 204.
45. Greenberg PL, Schiffer C, Koller CA, Glynos T, Paley C. Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of deferasirox (DFX/Exjade®) therapy in a cohort of myelodysplastic patients. Blood. 2008;112(11):abstr 5083.
46. List AF, Baer MR, Steensma D, et al. Iron chelation with deferasirox (Exjade®) improves iron burden in patients with myelodysplastic syndromes (MDS). Blood. 2008;112(11):abstr 634.
47. Wimazal F, Nosslinger T, Baumgartner C, Sperr WR, Pfeilstocker M, Valent P. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. Eur J Clin Invest. 2009; 39: 406-411.
48. Min YH, Kim HJ, Lee KH, et al. A multi-center, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R2 MRI. Blood. 2008;112(11):abstr 3649.
49. Messa E, Cilloni D, Messa F, et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008;120(2):70-74.
50. Gattermann N, Schmid M, Guerci-Bresler A, et al. Reduction in serum ferritin (SF) is associated with improvement in liver transaminase levels during treatment with deferasirox (Exjade®) in iron overloaded patients with myelodysplastic syndromes (MDS). Leuk Res. 2009;33(Suppl 1): S140-S141 (abstr P140).
51. Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin. 2009;25(1):139-147.
52. Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981;304(6):319-324.
53. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83:858-861.
54. Gattermann N, Porter J, Lopes LF, et al. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am. 2005;19(Suppl 1):18-25.
55. Vichinsky E, Coates T, Thompson AA, et al. Deferasirox (Exjade®), the once-daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): 3.5-year follow-up. Blood. 2008;112(11):abstr 1420.
56. Cancado R, Olivato MC, Bruniera P, Chiattone C. Deferasirox for the treatment of transfusional iron overload in sickle cell anemia: a 1-yr prospective study. Haematologica. 2009;94(Suppl 2):abstr 210.
57. Voskaridou E, Douskou M, Plata E, et al. Treatment with deferasirox effectively decreases iron burden in patients with sickle cell syndromes. Haematologica. 2009;94(Suppl 2):abstr 215.
58. Rose C, Gattermann N, Glimm E, Rabault B. Deferasirox (Exjade, ICL670), the novel, once-daily oral iron chelator, is well tolerated and effective in treating transfusional iron overload in patients with a range of rare anaemias. Haematologica. 2006;91(Suppl 1):abstr 22.
59. Tchernia G, Vichinsky E, Jeng M, et al. The once-daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in Diamond-Blackfan anaemia patients. Haematologica. 2005;90(Suppl 2):192.
60. Piga A, Kebaili K, Galanello R, et al. Cumulative efficacy and safety of 5-year deferasirox (Exjade®) treatment in pediatric patients with thalassemia major: a Phase II multicenter prospective trial. Blood. 2008;112(11):abstr 5413.
61. Taher A, Al Jefri A, Elalfy MS, et al. Deferasirox (Exjade®) treatment in pediatric β-thalassemia patients with high iron burden: 2.8 years results from ESCALATOR trial. Blood. 2008;112(11):abstr 3879.
62. Kruszewski M. The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol. 2004;51(2):471-480.
63. Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102:2670-2677.
64. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia. Eur J Haematol. 2009;82(5):454-457.
65. Porter JB, Cappellini MD, El-Beshlawy A, et al. Effect of deferasirox (Exjade®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-year EPIC trial. Blood. 2008;112(11):abstr 3881.
66. Ghoti H, Fibach E, Merkel D, et al. Decrease in intra- and extra-cellular free iron species and oxidative stress parameters and increase in serum and urinary hepcidin during treatment with deferasirox in iron-loaded patients with MDS. Haematologica. 2009;94(Suppl 2):abstr 797.
67. Bennett W, Ponticelli C, Piga A, Kattamis A, Glimm E, Ford J. Summary of long-term renal safety data in transfused patients with secondary iron overload receiving deferasirox (Exjade®, ICL670). Blood. 2006;108(11): abstr 3816.
68. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000;(314):1-27.
69. Vichinsky E, Coates T, Thompson A, et al. Safety and efficacy of iron chelation therapy with deferasirox in patients with sickle cell disease (SCD): 3.5-year follow-up. Haematologica. 2009;94(Suppl 2): abstr 200.
70. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314(14):869-873.
71. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73(3):403-409.
72. Porter JB, Piga A, Cohen A, Ford JM, Bodner J, Cappellini MD. Assessment of safety in patients receiving longer-term iron chelation therapy with deferasirox who had achieved serum ferritin levels of <1000 ng/mL during the study course. Haematologica. 2009; 94(Suppl 2):abstr 199.
73. Porter JB, Piga A, Cohen A, et al. Safety of deferasirox (Exjade®) in patients with transfusion-dependent anemias and iron overload who achieve serum ferritin levels <1000 ng/mL during long-term treatment. Blood. 2008;112(11):abstr 5423.
74. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-573.
75. Renfroe JL, Forbes P, Braunstein J, Neufeld EJ. Relationship of transfusion and iron-related complications to cost of care in thalassemia. Blood. 2005;106(11):abstr 2240.
76. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients. US healthcare system perspective. Pharmacoeconomics. 2007;25(4):329-342.
77. Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin. 2008;24(6):1609-1621.
78. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther. 2007;29(5):909-917.
79. Porter JB, Bowden D, Ganser A, et al. Satisfaction and adherence significantly improves in patients with β-thalassemia and myelodysplastic syndromes treated with deferasirox (Exjade®). Blood. 2008;112(11): abstr 1306.
80. Taher A, Al Jefri A, Elalfy M, et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: Results from ESCALATOR trial. Haematologica. 2008;93(Suppl 1):abstr 799.
81. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade®, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label Phase II trial. Acta Haematol. 2008;119(3): 133-141.
82. Porter JB, Bowden D, Ganser A, et al. Improved health-related quality of life in patients with hematological disorders receiving deferasirox (Exjade®). Blood. 2008;112(11):abstr 1307.
83. Aldouri MA, Wonke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990;84(3):113-117.
84. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348-355.
85. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia. Blood. 2000;95(4):1229-1236.